How Druggable Is Protein Kinase CK2?

被引:55
|
作者
Cozza, Giorgio [1 ]
Bortolato, Andrea [1 ]
Moro, Stefano [1 ]
机构
[1] Univ Padua, Dept Pharmaceut Sci, MMS, I-35131 Padua, Italy
关键词
protein kinase CK2; REGULATORY BETA-SUBUNIT; STRUCTURE-BASED DESIGN; ANGIOTENSIN-CONVERTING ENZYME; COMPETITIVE INHIBITOR EMODIN; DNA TOPOISOMERASE-II; RIBOSOMAL-P PROTEINS; BREAST-CANCER CELLS; CASEIN KINASE-2; ALPHA-SUBUNIT; CATALYTIC-SUBUNIT;
D O I
10.1002/med.20164
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
CK2 is a pleiotropic, ubiquitous, and constitutively active protein kinase (PK), with both cytosolic and nuclear localization in most mammalian cells. The holoenzyme is generally composed of two catalytic (alpha and/or alpha') and two regulatory (beta) subunits, but the free alpha/alpha' subunits are catalytically active by themselves and can be present in cells under some circumstances. CK2 catalyzes the phosphorylation of more than 300 substrates characterized by multiple acidic residues surrounding the phosphor-acceptor amino acid, and, consequently, it plays a key role in several physiological and pathological processes. But how can one kinase orchestrate all these tasks faithfully? How is it possible that one kinase can, despite all pleiotropic characteristics of PKs in general, be involved in so many different biochemical events? Is CK2 a druggable target? Several questions are still to be clearly answered, and this review is an occasion for a fruitful discussion. (C) 2009 Wiley Periodicals, Inc. Med Res Rev, 30, No. 3, 419-462, 2010
引用
收藏
页码:419 / 462
页数:44
相关论文
共 50 条